CRP/prealbumin, a novel inflammatory index for predicting recurrence after radical resection in gastric cancer patients: post hoc analysis of a randomized phase III trial

被引:80
|
作者
Lu, Jun [1 ,2 ]
Xu, Bin-bin [1 ,2 ]
Zheng, Zhi-fang [1 ,2 ]
Xie, Jian-wei [1 ,2 ]
Wang, Jia-bin [1 ,2 ]
Lin, Jian-xian [1 ,2 ]
Chen, Qi-yue [1 ,2 ]
Cao, Long-long [1 ,2 ]
Lin, Mi [1 ,2 ]
Tu, Ru-hong [1 ,2 ]
Huang, Ze-ning [1 ,2 ]
Zheng, Chao-hui [1 ,2 ]
Huang, Chang-Ming [1 ,2 ]
Li, Ping [1 ,2 ]
机构
[1] Fujian Med Univ, Dept Gastr Surg, Union Hosp, 29 Xinquan Rd, Fuzhou 350001, Fujian, Peoples R China
[2] Fujian Med Univ, Key Lab, Minist Educ Gastrointestinal Canc, Fuzhou, Fujian, Peoples R China
关键词
Gastric cancer; Inflammatory index; CRP; prealbumin; Recurrence; Post-recurrence survival; C-REACTIVE PROTEIN; NEUTROPHIL-LYMPHOCYTE RATIO; PROGNOSTIC-SIGNIFICANCE; PROTEIN/ALBUMIN RATIO; POOR-PROGNOSIS; SURVIVAL; ALBUMIN; PREALBUMIN; CARCINOMA; ADENOCARCINOMA;
D O I
10.1007/s10120-018-0892-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundSerum prealbumin (PALB) can predict the prognosis of patients with gastric cancer (GC). However, the prognostic value of combination of C-reactive protein and PALB (CRP/PALB) remains unclear.MethodsA total of 419 gastric cancer patients included in a clinical trial (NCT02327481) were analyzed. The present study is a substudy of the trial. Receiver operating characteristic (ROC) curves were generated, and by calculating the areas under the curve (AUC) and the C-index, the discriminative ability of each inflammatory index was compared, including CRP/PALB, C-reactive protein/albumin, Glasgow prognostic score (GPS), modified GPS, systemic immune-inflammation index, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio.ResultsUltimately, 401 patients were included in this study. The optimal cutoff value of CRP/PALB was 17.7. According to this cutoff point, the entire sample was divided into a CRP/PALB<17.7 (LCP) group and a CRP/PALB17.7 (HCP) group, comprising 245 and 156 patients, respectively. There were 54 and 22 patients experienced recurrence in the HCP and LCP group, respectively, p<0.001. Compared with traditional inflammatory indices, CRP/PALB had the highest AUC (0.707) and C-index (0.716), all p<0.05. The post-recurrence survival (PRS) of patients in the HCP group was significantly shorter than that in the LCP group (p=0.010), especially for pathological stage III patients (p=0.015) or patients with distant (p=0.018) orlocal (p=0.023) recurrences.ConclusionsThe predictive value of preoperative CRP/PALB for the recurrence of GC is significantly better than traditional inflammatory indices. HCP significantly reduces the PRS, especially for pathological stage III patients orpatients with distant or local recurrences.
引用
收藏
页码:536 / 545
页数:10
相关论文
共 36 条
  • [31] A novel nomogram for predicting post-operative recurrence for patients with intermediate and high-risk non-muscle invasive bladder cancer after thulium laser resection of bladder tumors or conventional transurethral resection of bladder tumors followed by intravesical bacille Calmette-Guérin immunotherapy
    Xu, Meng-Yao
    Sun, Jian-Xuan
    Xiang, Yu-Xi
    Hua, Zi-Jin
    Liu, Chen-Qian
    An, Ye
    Xu, Jin-Zhou
    Zhang, Si-Han
    Liu, Zheng
    Wang, Shao-Gang
    Xia, Qi-Dong
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2025, 14 (01)
  • [32] Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial
    Hironaka, Shuichi
    Ueda, Shinya
    Yasui, Hirofumi
    Nishina, Tomohiro
    Tsuda, Masahiro
    Tsumura, Takehiko
    Sugimoto, Naotoshi
    Shimodaira, Hideki
    Tokunaga, Shinya
    Moriwaki, Toshikazu
    Esaki, Taito
    Nagase, Michitaka
    Fujitani, Kazumasa
    Yamaguchi, Kensei
    Ura, Takashi
    Hamamoto, Yasuo
    Morita, Satoshi
    Okamoto, Isamu
    Boku, Narikazu
    Hyodo, Ichinosuke
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (35) : 4438 - +
  • [33] TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy
    Bardia, Aditya
    Pusztai, Lajos
    Albain, Kathy
    Ciruelos, Eva Maria
    Im, Seock-Ah
    Hershman, Dawn
    Kalinsky, Kevin
    Isaacs, Claudine
    Loirat, Delphine
    Testa, Laura
    Tokunaga, Eriko
    Wu, Jiong
    Dry, Hannah
    Barlow, William
    Kozarski, Robert
    Maxwell, Micah
    Harbeck, Nadia
    Sharma, Priyanka
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [34] A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial
    Park, S. H.
    Lim, D. H.
    Sohn, T. S.
    Lee, J.
    Zang, D. Y.
    Kim, S. T.
    Kang, J. H.
    Oh, S. Y.
    Hwang, I. G.
    Ji, J. H.
    Shin, D. B.
    Yu, J., I
    Kim, K-M
    An, J. Y.
    Choi, M. G.
    Lee, J. H.
    Kim, S.
    Hong, J. Y.
    Park, J. O.
    Park, Y. S.
    Lim, H. Y.
    Bae, J. M.
    Kang, W. K.
    ANNALS OF ONCOLOGY, 2021, 32 (03) : 368 - 374
  • [35] Evaluation of the in fl ammation-based modi fi ed Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving fi rst-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)
    Boukovala, M.
    Modest, D. P.
    Ricard, I.
    von Weikersthal, L. Fischer
    Decker, T.
    Vehling-Kaiser, U.
    Uhlig, J.
    Schenk, M.
    Freiberg-Richter, J.
    Peuser, B.
    Denzlinger, C.
    Reddemann, C. Peveling Genannt
    Graeven, U.
    Schuch, G.
    Schwaner, I.
    Heinrich, K.
    Neumann, J.
    Jung, A.
    Held, S.
    Stintzing, S.
    Heinemann, V.
    Michl, M.
    ESMO OPEN, 2024, 9 (05)
  • [36] Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
    Kang, Jin Hyoung
    Ahn, Myung-Ju
    Kim, Dong-Wan
    Cho, Eun Kyung
    Kim, Joo-Hang
    Shin, Sang Won
    Wang, Xin
    Kim, Jong Seok
    Orlando, Mauro
    Park, Keunchil
    CANCER RESEARCH AND TREATMENT, 2016, 48 (02): : 458 - 464